490 related articles for article (PubMed ID: 35020589)
1. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.
Galmiche S; Luong Nguyen LB; Tartour E; de Lamballerie X; Wittkop L; Loubet P; Launay O
Clin Microbiol Infect; 2022 Feb; 28(2):163-177. PubMed ID: 35020589
[TBL] [Abstract][Full Text] [Related]
2. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
[TBL] [Abstract][Full Text] [Related]
4. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.
Wang X; Haeussler K; Spellman A; Phillips LE; Ramiller A; Bausch-Jurken MT; Sharma P; Krivelyova A; Vats S; Van de Velde N
Front Immunol; 2023; 14():1204831. PubMed ID: 37771594
[TBL] [Abstract][Full Text] [Related]
6. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
9. One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort.
Loubet P; Wittkop L; Ninove L; Chalouni M; Barrou B; Blay JY; Hourmant M; Thouvenot E; Laville M; Laviolle B; Lelievre JD; Morel J; Quoc SN; Spano JP; Terrier B; Thiebaut A; Viallard JF; Vrtovsnik F; Circosta S; Esterle L; Levier A; Vanhems P; Tartour E; Parfait B; de Lamballerie X; Launay O;
Clin Microbiol Infect; 2023 Mar; 29(3):388.e1-388.e8. PubMed ID: 36252789
[TBL] [Abstract][Full Text] [Related]
10. Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS).
Haidar G; Agha M; Bilderback A; Lukanski A; Linstrum K; Troyan R; Rothenberger S; McMahon DK; Crandall MD; Sobolewksi MD; Nathan Enick P; Jacobs JL; Collins K; Klamar-Blain C; Macatangay BJC; Parikh UM; Heaps A; Coughenour L; Schwartz MB; Dueker JM; Silveira FP; Keebler ME; Humar A; Luketich JD; Morrell MR; Pilewski JM; McDyer JF; Pappu B; Ferris RL; Marks SM; Mahon J; Mulvey K; Hariharan S; Updike GM; Brock L; Edwards R; Beigi RH; Kip PL; Wells A; Minnier T; Angus DC; Mellors JW
Clin Infect Dis; 2022 Aug; 75(1):e630-e644. PubMed ID: 35179197
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis.
Manley HJ; Li NC; Aweh GN; Hsu CM; Weiner DE; Miskulin D; Harford AM; Johnson D; Lacson E
Am J Kidney Dis; 2023 Apr; 81(4):406-415. PubMed ID: 36462570
[TBL] [Abstract][Full Text] [Related]
12. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
Thuluvath PJ; Robarts P; Chauhan M
J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
[TBL] [Abstract][Full Text] [Related]
13. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F
J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083
[TBL] [Abstract][Full Text] [Related]
14. Humoral response after a fourth dose of SARS-CoV-2 vaccine in immunocompromised patients. Results of a systematic review.
Martinelli S; Pascucci D; Laurenti P
Front Public Health; 2023; 11():1108546. PubMed ID: 37033069
[TBL] [Abstract][Full Text] [Related]
15. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of SARS-CoV-2 vaccine in hemodialysis patients: A systematic review and meta-analysis.
Peiyao R; Mengjie Y; Xiaogang S; Wenfang H; Danna Z; Yuqun Z; Juan J; Qiang H
Front Public Health; 2022; 10():951096. PubMed ID: 36211647
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.
Subramanian V
J Infect Dis; 2023 Aug; 228(Suppl 1):S34-S45. PubMed ID: 37539762
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]